Asthma Shot Readiness

Executive summary

A twice-yearly asthma injection just moved from concept to pharmacy shelf — and patients are cautiously ready. GSK's Exdensur (depemokimab) received FDA approval in December 2025, making it the first ultra-long-acting biologic dosed just twice a year for severe asthma. A 204-person survey conducted around that milestone reveals a market that is interested but not yet sold, and shows exactly which message unlocks the most skeptical patients.

The single most powerful finding: 69% of respondents shifted positively in their view of the biannual injection after learning clinical trials showed it to be safer than traditional daily pills. That's not a soft nudge — nearly one in three moved very positively. In a polarized sample, that kind of movement from a single piece of evidence signals that safety framing isn't just helpful messaging; it's the conversion lever.

Meanwhile, the treatment landscape these patients come from tells its own story. Rescue inhalers — reactive, symptom-chasing medicine — are the dominant therapy at 33.7% of treatment mentions, while long-term controller medications sit at just 10%. That gap mirrors CDC data showing half of American adults with asthma have uncontrolled disease. Exdensur is entering a market full of under-managed patients who already know their current approach isn't working.

Context

For the roughly 25 million Americans living with asthma — and the estimated 2 million with severe, hard-to-control disease — the daily management burden is real and largely invisible to everyone else. Inhalers get forgotten, controller medications go unfilled, and half of all adults with asthma have disease that remains uncontrolled despite available treatments, according to CDC data. The search for something better has driven the asthma biologic market to $18.2 billion and counting.

This study surveyed 204 people about a specific innovation: a physician-administered injection given just twice a year that replaces the daily inhaler or pill regimen. At the time of survey design, this was a near-future concept. By December 16, 2025, it was a real FDA-approved product — GSK's Exdensur (depemokimab), cleared for adults and adolescents 12 and older with severe eosinophilic asthma. The SWIFT-1 and SWIFT-2 Phase 3 trials, published in the New England Journal of Medicine, showed 58% and 48% reductions in annual asthma attacks versus placebo, with an adverse event profile statistically comparable to placebo across 762 patients at 331 sites in 23 countries.

The survey asked five questions: what treatments respondents currently use, whether they'd want the biannual injection, how safety data from clinical trials affected their opinion, their gut reactions and doubts, and when they were diagnosed. About one-third of respondents (32.8%) reported not having asthma, making this a mixed sample of chronic patients, recently diagnosed individuals, and curious or at-risk non-patients — a cross-section that mirrors the realistic audience for early-stage health technology awareness.

The context matters because the approval of Exdensur transforms these survey results from a speculative readiness check into a direct commercial signal. Pharma teams, patient advocacy groups, and healthcare providers now face an immediate adoption challenge: how do you move a polarized patient population toward a twice-yearly injection when rescue inhalers are the path of least resistance and needle phobia affects nearly two-thirds of adults?

Findings

Conclusion

Exdensur is on shelves. The question is no longer whether patients will encounter a biannual asthma injection — it's whether the people who need it most will say yes when their doctor brings it up.

This survey points to three concrete priorities for anyone involved in patient communication or market strategy. First, lead with safety data, not convenience. The 69% positive shift after one safety-framing prompt is the clearest signal in the dataset. Patients who hear "safer than daily pills, with physician-controlled dosing and placebo-level adverse events in 762-patient trials" respond. Those who hear "one shot, skip the daily inhaler" remain skeptical. Second, target the rescue-only population directly. The 33.7% rescue-inhaler majority represents patients already experiencing uncontrolled asthma — the exact clinical profile Exdensur was built for. These patients aren't rejecting controller therapy; many have simply never been meaningfully offered it. Third, take needle phobia seriously as a structural barrier, not a messaging problem. Nearly two-thirds of adults carry some degree of injection aversion. Physician-administered settings, patient preparation materials, and honest conversations about what the shot involves are table stakes — not optional.

Watch the 27.4% neutral bloc. That's the persuadable middle, and as real-world Exdensur safety data accumulates post-launch, the evidence-demand barrier these patients cited will shrink. The next 12–18 months of post-market surveillance data may be the most important patient-facing asset the category produces.